数量上的强度:从大型临床数据集预测检查点抑制剂的反应
Albrecht Stenzinger1, Daniel Kazdal2, Solange Peters3
1Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg partner site, Heidelberg, Germany; German Center for Lung Research (DZL), Heidelberg partner site, Heidelberg, Germany.
Cell
|January 28, 2021
概括
研究人员确定了基因组生物标志物来预测癌症免疫治疗的反应. 这种跨不同癌症类型的大数据分析为精准医学和治疗选择提供了新的工具.
科学领域:
- 癌症学
- 免疫学
- 基因组学
背景情况:
- 免疫检查点阻断剂已经彻底改变了癌症治疗.
- 鉴定免疫治疗反应的预测生物标志物对于治疗优化至关重要.
- 了解瘤免疫的复杂性是开发有效癌症治疗的关键.
研究的目的:
- 识别可预测免疫疗法反应的基因组生物标志物.
- 通过大数据分析发现跨癌症预测标记.
- 在瘤学领域推进精确医学.
主要方法:
- 进行了全面的大数据分析.
- 使用了最大数量的同质化分子和临床数据集.
- 使用先进的分析方法来识别基因组特征.
主要成果:
- 确定了一组基因组生物标志物.
- 这些生物标志物预测免疫治疗反应.
- 这些发现适用于各种癌症类型.
结论:
- 基因组生物标志物可以有效预测免疫治疗反应.
- 大数据方法对于瘤学中的生物标志物发现具有强大作用.
- 这些发现支持个性化癌症治疗的发展.
相关概念视频
Factors Affecting Drug Response: Overview
3.1K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.1K
Quantitative Aspects of Drug-Receptor Interaction
2.2K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
2.2K
Drug Product Performance: In Vitro–In Vivo Correlation
431
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
431
Therapeutic Drug Monitoring: Affecting Factors
429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97


